Personalis Inc

Description

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patientâ??s cancer and immune response. They designed their NeXT Platform to adapt to the complex and evolving understanding of cancer, providing their biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover roughly 50 to 500 genes. They are also developing a complementary liquid biopsy assay that analyzes all human genes versus the more narrowly focused liquid biopsy assays that are currently available. By combining technological innovation, operational scale, and regulatory differentiation, their NeXT Platform is designed to help their customers obtain new insights into the mechanisms of response and resistance to therapy as well as new potential therapeutic targets. Their platform enhances the ability of biopharmaceutical companies to unlock the potential of conducting translational research in the clinic rather than with pre-clinical animal models or cancer cell lines. They are also planning to release a diagnostic based on their NeXT Platform that they envision being used initially by biopharmaceutical customers and clinical collaborators. Since inception, they have provided their services to more than 45 biopharmaceutical customers, including several of the largest pharmaceutical companies in the world. Personalis, Inc. were incorporated under the laws of the state of Delaware in February 2011 under the name Personalis, Inc. Their principal executive offices are located at 1330 Oâ??Brien Drive, Menlo Park, California 94025.